factors obscuring placebo effects include the natural course of the disease, regression to the mean and the impact of comorbidities [39] . Variations in placebo responses cannot be attributed to selection bias, unblinding and other methodological shortcomings [40] [41] [42] [43] [44] . Learning may have an impact, especially when patients participate in several RCTs [45] .
Better understanding of the placebo response in RA will facilitate its judicious use in future RCTs. We therefore evaluated which outcome measures most contribute to placebo responses after 6 and 12 months of blinded treatment in two large RCTs of DMARDs. These may be among the last large RCTs employing 4-6 months of placebo treatment without background DMARDs or rescue therapy [6, 10] , as RA patients receiving placebo for over 6 months may experience irreversible deterioration in physical function [44, 46, 47] .
Patients and methods

Study design
In MN301, a 6-month multicentre RCT, 358 patients were randomized to leflunomide, placebo, or sulphasalazine in a 3:2:3 ratio; 92 patients received placebo [10] . US301, a 24-month multicenter RCT, enrolled 482 patients to receive leflunomide, placebo or methotrexate in a 3:2:3 ratio; 118 patients received placebo [6] . When MN301 was designed, it was considered unethical to allow patients with active RA to receive placebo for >6 months; those completing 6 months' protocol treatment were offered blinded continuation therapy with sulphasalazine in an extension trial, MN303. In US301, with documented lack of efficacy [failure to achieve ACR !20% response criteria] on or after 4 months of protocol treatment, blinded alternate active therapy was offered to all patients, determined at initial randomization. Patients randomized to receive leflunomide were switched to methotrexate, and those initially receiving methotrexate or placebo to leflunomide treatment.
Patients
Patients !18 yr old with RA by ACR criteria were enrolled in both RCTs with protocol-specified criteria for active disease [48] . Patients could not have received prior treatment with the active comparator (MN301: sulphasalazine; US301: methotrexate). Other DMARDs were to have been discontinued !28 days prior to enrolment; concomitant prednisone ( 10 mg/d or equivalent) and NSAID doses were to remain stable !28 days prior to enrolment and during protocol participation. The RCTs were conducted in accordance with ethical review boards, good clinical research practice and the Declaration of Helsinki [22] .
Efficacy measures
Primary outcome measures in both trials were ACR20 responses at 6 (MN301) and 12 (US301) months. In MN301, mean HAQ scores were used and in US301 modified health assessment questionnaire (MHAQ) scores were used to calculate ACR responses. In both studies the HAQ Disability Index [HAQ DI] was assessed at baseline and 6-month intervals [6, 10] . In US301, PET and SF-36 were also included [7, 8] . Physician-reported measures included swollen joint count (SJC), tender joint count (TJC) and global assessment of disease activity. Both protocols used 28-joint counts; mean changes from baseline were assessed. Patient-reported outcomes included global assessments of disease activity, pain, mean HAQ and MHAQ as components of ACR response criteria and HAQ DI (as well as PET and SF-36 in US301). Changes in ESR and CRP were also compared.
Statistical analyses
Statistical analyses used the intent-to-treat (ITT) population, with last observation carried forward (LOCF) and analysis of covariance (ANCOVA) for continuous variables. Five-point Likert scores used in MN301 for patient and physician global assessments were converted to 1-100 visual analogue scale (VAS) scores. Observed treatment effects were calculated as percentage differences between mean changes in active and placebo treatment groups as follows: gross percentage change at endpoint ¼ (mean change at endpoint/mean baseline) Â 100 and individual percentage change at endpoint ¼ sum (individual change at endpoint/individual baseline)/n Â 100. (Percentage improvements are positive; deteriorations are negative.) To evaluate relative magnitudes of change, SESs were calculated for each ACR response component and for HAQ DI, PET and SF-36. To be consistent with the majority of response components, for which improvements are reported as decreased scores, SESs are presented with negative changes indicating improvement. Direct statistical comparisons between active and placebo treatments for each efficacy measure have been published; statistical comparisons of derived SES were not conducted.
Results
Demographic and baseline disease characteristics were comparable between treatment groups in both RCTs. Efficacy between active treatments were superior to placebo and did not differ statistically from each other, as published previously [6, 10] .
Mean percentage change (gross %) and individual percentage changes (individual %) from baseline in physician-and patientreported and laboratory outcomes in active and placebo-treated groups in MN301 and US301 are presented in Table 1 and are similar to each other. In MN301, physician-based assessments at 6 months (TJC, SJC and physician global assessments) improved by 38-52% with leflunomide, 40-49% with sulphasalazine and 11-26% with placebo; at 12 months in US 301 they improved by an average of 41-53% with leflunomide, 39-43% with methotrexate and 15-20% with placebo. At 6 months in MN301, patientreported outcomes (patient global assessment, pain, mean HAQ and HAQ DI) improved by 33-43% with leflunomide and 24-40% with sulphasalazine, and ranged from 20% worsening to 15% improvement with placebo treatment (Table 1 , Fig. 1 ). In US301, patient-reported assessments at 12 months (patient global assessment, pain, MHAQ, HAQ DI, PET and SF-36 Physical Component Score) improved by 24-38% with leflunomide and 5-29% with methotrexate, and ranged from 16% worsening to 6% improvement with placebo (Table 1 In US301, mean individual percentage changes in patientreported pain and global assessment deteriorated with placebo treatment, whereas in MN301 patient global assessments improved (11.6%) and pain worsened (À20.4%). However, the magnitude of Gross % change at endpoint ¼ (mean change at endpoint/mean baseline) Â 100. 2 Individual % change at endpoint ¼ sum(individual change at endpoint/individual baseline)/n Â 100. 3 Excludes one outlier subject in placebo group (% change >2 standard deviations from the mean). Improvements in outcomes reported by patients with placebo treatment were less than physician-assessed measures, and uniformly showed deterioration in individual percentage changes in physical function. The laboratory measures ESR and CRP reflected worsening following placebo administration, according to mean gross and individual percentage changes and SES. In the placebo treatment groups, physician-reported measures showed improvement by mean gross and individual percentage changes as well as SES. In MN301, at 6 months, small improvements indicated by mean gross percentage changes and SES in patientreported pain, mean HAQ and HAQ DI were actually worsenings according to mean individual percentage changes (Fig. 1) . At 12 months, despite small improvements in gross percentage changes in patient global assessment of disease activity, pain and PET, worsening was evident by mean individual percentage 
Discussion and conclusions
These results show that patient-reported outcome measures are less susceptible to placebo effects than physician-reported measures. Self-report questionnaires and acute-phase reactants (ESR and CRP) better differentiated between active and placebo treatment. Physician-reported measures showed substantial improvements in group means and individual percentage changes in patients receiving placebo, although absolute differences in SESs between active and placebo treatments are similar to those with patient reported outcomes.
An early large meta-analysis of 130 placebo RCTs with NSAIDs showed that patient global assessment was the most sensitive effect measure, followed by patient-reported pain [49] . This study suggested that there was little justification for the widespread use of the Ritchie index. A subsequent RCT examining withdrawal of DMARDs in RA showed no differences between observer evaluations of joint counts despite significant differences in patient perceptions of treatment effect [50] . A later meta-analysis of 114 RCTs showed that in 32 trials with binary outcome measures there was no evidence of a placebo effect [41] . However, it also showed that in 82 RCTs with continuous outcome measures placebo treatment only showed benefits when subjective, not objective, endpoints were assessed. Significant, but small, improvements in patient reported pain with placebo treatment decreased with increasing sample size. Placebo responses in patient-reported outcomes may reflect non-specific effects in the patient-physician relationship, including attention, compassionate care, modulation of expectations, anxiety and self-awareness [51] . The two RCTs we have evaluated used a double-dummy treatment regimen in which all patients received three oral medications with control treatments identical to active therapies. The magnitude of placebo responses in both trials was similar to those reported in recent RCTs with biological DMARDs, where parenteral administration and separate observers were required for safety and efficacy, with potentially different expectation biases [52] .
Reported improvements and deteriorations were analysed by mean gross and individual percentage changes and SES. As all but PET and SF-36 are components of the ACR !20% response criteria, there is no gold standard that can be independently applied to the analyses. The Disease Activity Score (DAS28), which includes TJC, SJC, ESR and patient global assessment of disease activity, was retrospectively applied to both RCTs [53] Results indicated by DAS28 'good or moderate' improvements with placebo treatment were very similar to ACR20 responses. In MN301 at 6 months, 37% of patients receiving placebo were responders according to DAS28 compared with 29% according to ACR20 criteria in US301 at 12 months: 30 vs 26% respectively were identified as responders, indicating reasonable concordance assessing the placebo response by the use of both criteria [54] . In US301, 17% patients receiving placebo were classified as responders by ACR !20% criteria but not DAS28; 11% were classified as responders by DAS28 and not ACR criteria. [55] Less concordance identifying responders following active treatment was evident in US301: 0 and 7% by ACR but not DAS28 criteria with leflunomide and methotrexate respectively, and 28 and 33% by DAS28 but not ACR criteria.
The analyses, using prespecified outcome measures, depict differing views of the placebo response. Reported improvements with placebo administration are more prevalent with physicianreported measures. In both RCTs, differences in SES between active and placebo treatment were largest with patient-reported outcomes, particularly physical function. Whether assessed by HAQ DI, mean changes in HAQ or MHAQ scores, lack of improvement or deterioration was reported following placebo administration. The results indicate that patient-reported outcomes are objective, congruent with laboratory measures of inflammation, are less susceptible to the placebo response, and best discriminate active from placebo treatment. Results using these outcome measures should be emphasized in RCTs designed to measure clinical benefit in RA. Provided these observations can be replicated in analyses of other placebo RCTs in RA (with or without background therapy), the balance of evidence suggests that improvement in signs and symptoms of active disease is most accurately assessed using patient-reported physical function, provided similar changes are reported in global assessments of disease activity and pain, subsequently supported by improvements in other domains, including laboratory and imaging measures. Caution is needed when using the term 'placebo response', and the analysis of active and placebo treatment effects should separate patient-reported, physician-reported and laboratory measures.
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